A novel epigenetic biomarker, plasma miR-138-5p gene promoter-methylated DNA, for colorectal cancer diagnosis.

IF 1.7 4区医学 Q3 PHARMACOLOGY & PHARMACY

Personalized medicine Pub Date : 2022-06-17 DOI:10.2217/pme-2021-0095

Masoud Asefi, M. Saidijam, Nayebali Rezvani, A. Soltanian, A. Khalilian, Ali Mahdavinezhad

引用次数: 1

Abstract

Aim: The miR-138-5p promoter-methylated DNA level, miR-138-5p and PDL1 expression were investigated in colorectal cancer (CRC) patients. Materials & methods: miR-138-5p promoter methylation status and miR-138-5p expression were investigated using the MethyLight and qPCR method, respectively. For measuring PDL-1, we applied the Bioassay Technology Elisa kit. Results: The percentage of methylated reference values of plasma and tissue samples from patients was higher than control groups. The area under curve presented a sensitivity of 55% and a specificity of 82.5% for plasma samples. Compared with the control groups, lower expression of miR-138-5p and higher concentration of PDL1 protein were observed in the patients group. Conclusion: CRC may be detected early by identifying miR-138-5p methylated DNA in plasma as a diagnostic biomarker.

查看原文本刊更多论文

一种新的表观遗传生物标志物，血浆miR-138-5p基因启动子甲基化DNA，用于结直肠癌诊断。

目的：研究结直肠癌（CRC）患者体内miR-138-5p启动子甲基化DNA水平、miR-138-5 p和PDL1的表达。材料与方法：分别采用MethyLight和qPCR方法研究miR-138-5p启动子甲基化状态和miR-138-5-p表达。为了测量PDL-1，我们应用了生物测定技术Elisa试剂盒。结果：患者血浆和组织样本的甲基化参考值百分比高于对照组。曲线下面积对血浆样本的敏感性为55%，特异性为82.5%。与对照组相比，患者组的miR-138-5p表达较低，PDL1蛋白浓度较高。结论：通过鉴定血浆中miR-138-5p甲基化DNA作为诊断生物标志物，可以早期检测CRC。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Personalized medicine 医学-药学

CiteScore

3.30

自引率

4.30%

发文量

审稿时长

6-12 weeks

期刊介绍： Personalized Medicine (ISSN 1741-0541) translates recent genomic, genetic and proteomic advances into the clinical context. The journal provides an integrated forum for all players involved - academic and clinical researchers, pharmaceutical companies, regulatory authorities, healthcare management organizations, patient organizations and others in the healthcare community. Personalized Medicine assists these parties to shape thefuture of medicine by providing a platform for expert commentary and analysis. The journal addresses scientific, commercial and policy issues in the field of precision medicine and includes news and views, current awareness regarding new biomarkers, concise commentary and analysis, reports from the conference circuit and full review articles.